MedTrace Logo

Identification and Characterization of Ovarian Cancer and Endometrial Cancer Specific Biomarkers in Vaginal Fluids

NCT02704650 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-04-27

No results posted yet for this study

Summary

The purpose of this study is to:

1. Identification and characterization of ovarian carcinoma well-known biomarkers, carcinoma antigen 125 (CA125) and Human epididymis protein 4 (HE4) and other potential biomarkers in vaginal fluids obtained from ovarian cancer patients.
2. Quantification and calibration of identified biomarkers in vaginal discharge collected from ovarian cancer patients in comparisons to samples collected from healthy volunteers.
3. Comparison analysis of biomarkers levels in vaginal fluids vs. serum.
4. Quantification and calibration of identified biomarkers in vaginal discharge collected from ovarian cancer patients diagnosed in various stages.

Conditions

  • Cancer of Ovary

Interventions

PROCEDURE

fluid sample

taking a vaginal fluid sample

Sponsors & Collaborators

  • Gina-Life Diagnostics ltd.

    collaborator INDUSTRY

  • Shaare Zedek Medical Center

    lead OTHER

Principal Investigators

  • Shachar Finci, MD · Shaare Zedek Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2016-10-31
Completion
2017-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02704650 on ClinicalTrials.gov